Literature DB >> 1310834

Effects of nedocromil sodium, cromolyn sodium, and a placebo in exercise-induced asthma.

A R Morton1, S L Ogle, K D Fitch.   

Abstract

The incidence and severity of exercise-induced asthma were determined in nineteen asthmatic patients who performed eight minutes of exercise following four treatments administered in a random order. The treatments were nedocromil sodium, cromolyn sodium, placebo, and no treatment. It was concluded that nedocromil sodium (8 mg) and cromolyn sodium (4 mg) provide equal protection against exercise-induced asthma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310834

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  7 in total

Review 1.  Asthmatic drugs and competitive sport. An update.

Authors:  A R Morton; K D Fitch
Journal:  Sports Med       Date:  1992-10       Impact factor: 11.136

Review 2.  Treatment of childhood asthma: how do the available options compare?

Authors:  David Coghlan; Colin Powell
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 3.  Exercise-induced asthma and anaphylaxis.

Authors:  D O Hough; K L Dec
Journal:  Sports Med       Date:  1994-09       Impact factor: 11.136

Review 4.  Nedocromil sodium. An updated review of its pharmacological properties and therapeutic efficacy in asthma.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer.

Authors:  Khalid Abd-Elaziz; Hanneke Oude Elberink; Zuzana Diamant
Journal:  Eur Clin Respir J       Date:  2020-08-20

6.  Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist.

Authors:  James P Kemp
Journal:  Ther Clin Risk Manag       Date:  2009       Impact factor: 2.423

7.  The Effect of Cromolyn Sodium and Nedocromil Sodium Administered by A pressurized Aerosol with A spacer Device on Exercise-Induced Asthma in Children.

Authors:  F M de Benedictis; G Tuteri; A Niccoli; D Mezzetti; L Rossi; L Bruni
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.